药物诱导的牙疾病:来自FDA不良事件报告系统 (FAERS) 数据库的分析
Shun Mao1, Fei Ma1, Chang Zeng1
1School of Stomatology, Hunan University of Chinese Medicine, Changsha, China; Department of General Dentistry, Changsha Stomatological Hospital, Changsha, China.
European journal of pharmacology
|August 29, 2025
概括
这项研究分析了FDA的数据以确定导致牙疾病的药物. 83种药物显示出风险信号,包括骨质疏松症和心血管药物,帮助医疗保健提供者进行诊断.
科学领域:
- 药物监督管理
- 牙科医学
- 药物安全
背景情况:
- 药物诱导的牙疾病是一个重大的临床挑战.
- 了解药物与牙健康之间的关联对于患者护理至关重要.
研究的目的:
- 使用FDA不良事件报告系统 (FAERS) 数据库识别药物与牙疾病的潜在关联.
- 检测与牙不良事件相关的药物的安全信号.
主要方法:
- 对2004Q1至2024Q3的FAERS数据进行分析.
- 使用不相称性分析 (ROR,PRR,BCPNN,MGPS) 来检测不良事件信号.
- 患者人口统计和报告来源的描述性统计分析.
主要成果:
- 报告了与药物诱导的牙疾病相关的34354个不良事件.
- 83种药物显示出积极的风险信号,包括抗骨质疏松药物 (佐勒德龙酸,德诺苏马布,阿伦德龙酸) 和心血管药物 (阿姆洛迪平,里瓦罗克萨班).
- 女性和老年人更常受到影响;消费者是主要报告者.
结论:
- 在FAERS数据库分析中发现了与牙疾病风险增加相关的特定药物.
- 这些发现突显了某些药物的牙风险的潜在记录不足.
- 结果可以提高医疗保健提供者识别和管理药物诱导的牙疾病的能力.
相关概念视频
FDA Approved Drugs: Changes to Approved Drugs
66
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
66
Pharmacovigilance
1.3K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.3K
Drug Regulation
2.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.3K
Assessment of the Gastrointestinal System I: Subjective Data
414
Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
414
Oral Hypoglycemic Agents: Biguanides and Glitazones
416
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
416


